ANGLE chief highlights latest positive Parsortix data from USC

An American study has raised the prospect of a new UK-developed blood test taking the place of painful biopsies in metastatic breast cancer.

The University of Southern California (USC) Norris Comprehensive Cancer Center has been working with the Parsortix device, developed by AIM-listed ANGLE PLC (LON:AGL), to harvest circulating tumour cells.

Andrew Newland, chief executive of ANGLE, tells Proactive Investors that USC found, using its Parsortix device, “instead of having an invasive operation to cut out cancer cells from the secondary cancer, which is the standard of care in the United States, they can have a simple blood test”.

He adds that the benefits of this new type of treatment include that it can be repeated as many times as necessary, it quickens the diagnosis stage of treatment, and Parsortix is much cheaper than the surgery option.

Quick facts: ANGLE PLC

Price: 48.5 GBX

Market: AIM
Market Cap: £83.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read